Evolution of the Average Target: AstraZeneca PLC

Evolution of the Target Price: AstraZeneca PLC

Changes in Analyst Recommendations: AstraZeneca PLC

7ee56a148a3fab25dbb22e3be.mKIK-Mb2MclNTEubNjbwFeALXyndHvDjmnX9p4rku8I.-uBvu5fCZKU_OHL2Yny1bbJvDRifTImL2UWz3smX2qmp1Wu3orNwuSEIew~777968166f58cbc0668053a22197cc0a
08:57am Genmab in Good Health, Schneider Lacks Energy Zonebourse
06:02am BofA Forecasts 'In-line' Q3, Unchanged FY26 Outlook for AstraZeneca Amid Oncology Momentum MT
09-30 AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating ZD
09-29 AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says MT
09-29 Stocks Defy the Pressure Zonebourse
09-29 AstraZeneca PLC : Jefferies keeps its Buy rating ZD
09-29 AstraZeneca PLC : RBC reaffirms its Buy rating ZD
09-29 AstraZeneca PLC : JP Morgan maintains a Buy rating ZD
09-29 AstraZeneca PLC : Deutsche Bank is Neutral ZD
09-18 Berenberg and Deutsche say buy Bytes Technology AN
09-16 AstraZeneca PLC : Gets a Buy rating from UBS ZD
09-16 Oddo BHF cuts Safestore to neutral, cuts target AN
09-16 AstraZeneca PLC : Buy rating from Jefferies ZD
09-16 AstraZeneca PLC : JP Morgan keeps its Buy rating ZD
09-16 AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down MT
09-15 Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says MT
09-15 Deutsche Bank Upgrades AstraZeneca to Hold, Lifts PT MT
09-15 Berenberg Trims Price Target on AstraZeneca to $203 From $214, Keeps Buy Rating MT
09-15 Berenberg Maintains AstraZeneca at Buy as Pipeline Success Offsets Recent Setbacks; Price Target Down MT
09-15 Berenberg likes GSK; Deutsche Bank lifts Astra AN
09-15 AstraZeneca PLC : Berenberg keeps its Buy rating ZD
09-15 AstraZeneca PLC : Deutsche Bank withdraws its Sell rating ZD
09-14 AstraZeneca PLC : JP Morgan reiterates its Buy rating ZD
09-14 AstraZeneca PLC : Jefferies reiterates its Buy rating ZD
09-10 Berenberg Notes AstraZeneca's 'Stellar' Tozorakimab Late-stage Data; Buy Retained MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+16.25%
+10.5%
+4.93%
+12.05%
+7.67%
+8.24%
+34.74%
-2.99%
+9.7%
Average +11.23%
Weighted average by Cap. +11.85%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
155.54USD
Average target price
209.57USD
Spread / Average Target
+34.74%
High Price Target
267.78USD
Spread / Highest target
+72.17%
Low Price Target
157.72USD
Spread / Lowest Target
+1.40%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
-